PET imaging of dopamine-D2 receptor internalization in schizophrenia

被引:0
|
作者
J J Weinstein
E van de Giessen
R J Rosengard
X Xu
N Ojeil
G Brucato
R B Gil
L S Kegeles
M Laruelle
M Slifstein
A Abi-Dargham
机构
[1] Stony Brook University School of Medicine,Department of Psychiatry
[2] SUNY at Stony Brook,undefined
[3] Health Sciences T10-041-L,undefined
来源
Molecular Psychiatry | 2018年 / 23卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Recent genetic, molecular and post-mortem studies suggest impaired dopamine (DA)-D2 receptor (D2R) trafficking in patients with schizophrenia (SZ). Imaging and preclinical studies have shown agonist-induced D2R internalization can be imaged with positron emission tomography (PET) using D2R radiotracers combined with psychostimulant challenge. This is feasible if radiotracer binding is measured when postchallenge DA levels have returned to baseline, following the initial competition phase between DA and radiotracer for binding to D2R. Here we used ‘late-phase' imaging after challenge to test the hypothesis that impaired D2R internalization in SZ leads to blunted late-phase displacement, or a faster return to baseline, in patients compared with healthy controls (HCs). We imaged 10 patients with SZ and 9 HCs with PET and [11C]raclopride at baseline and two times (3–5 and 6–10 h) following 0.5 mg kg−1 dextroamphetamine. We measured binding potential relative to non-displaceable compartment (BPND) and derived percent reduction from baseline (ΔBPND) for each postamphetamine scan. To test the hypothesis that time course of return of striatal BPND to baseline differed between SZ and HCs, we implemented a linear model with ΔBPND as dependent variable, time after amphetamine as repeated measure and time after amphetamine and diagnostic group as fixed effects. Neither diagnostic group nor interaction of diagnostic group-by-time after amphetamine significantly affected striatal ΔBPND (F=1.38, P=0.26; F=0.51, P=0.61). These results show similar pattern of return of BPND to baseline as a function of time in patients with SZ and HC, suggesting that striatal D2R internalization as measured by our imaging paradigm is normal in patients with SZ.
引用
收藏
页码:1506 / 1511
页数:5
相关论文
共 50 条
  • [31] NMDA RECEPTOR ANTAGONISTS INHIBIT CATALEPSY INDUCED BY EITHER DOPAMINE-D1 OR DOPAMINE-D2 RECEPTOR ANTAGONISTS
    MOORE, NA
    BLACKMAN, A
    AWERE, S
    LEANDER, JD
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 237 (01) : 1 - 7
  • [32] VALIDATION OF QUANTITATIVE BRAIN DOPAMINE-D2 RECEPTOR IMAGING WITH A CONVENTIONAL SINGLE-HEAD SPET CAMERA
    NIKKINEN, P
    LIEWENDAHL, K
    SAVOLAINEN, S
    LAUNES, J
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1993, 20 (08): : 680 - 683
  • [33] DECREASE IN HUMAN STRIATAL DOPAMINE-D2 RECEPTOR DENSITY WITH AGE - A PET STUDY WITH [C-11] RACLOPRIDE
    RINNE, JO
    HIETALA, J
    RUOTSALAINEN, U
    SAKO, E
    LAIHINEN, A
    NAGREN, K
    LEHIKOINEN, P
    OIKONEN, V
    SYVALAHTI, E
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1993, 13 (02): : 310 - 314
  • [34] SEPARATION OF DOPAMINE-D1 AND DOPAMINE-D2 RECEPTORS
    DUMBRILLEROSS, A
    NIZNIK, H
    SEEMAN, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 110 (01) : 151 - 152
  • [35] DOPAMINE-D2 RECEPTOR AGENTS, BUT NOT DOPAMINE-D1, MODIFY BRAIN GLUCOSE-METABOLISM
    PALACIOS, JM
    WIEDERHOLD, KH
    BRAIN RESEARCH, 1985, 327 (1-2) : 390 - 394
  • [36] DOPAMINE-D2 RECEPTOR-BINDING SITES FOR AGONISTS - A TETRAHEDRAL MODEL
    SEEMAN, P
    WATANABE, M
    GRIGORIADIS, D
    TEDESCO, JL
    GEORGE, SR
    SVENSSON, U
    NILSSON, JLG
    NEUMEYER, JL
    MOLECULAR PHARMACOLOGY, 1985, 28 (05) : 391 - 399
  • [37] ALLELIC ASSOCIATION OF HUMAN DOPAMINE-D2 RECEPTOR GENE IN ALCOHOLISM - REPLY
    BLUM, K
    NOBLE, EP
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (14): : 1808 - 1809
  • [38] THE DOPAMINE-D2 RECEPTOR - 2 MOLECULAR-FORMS GENERATED BY ALTERNATIVE SPLICING
    DALTOSO, R
    SOMMER, B
    EWERT, M
    HERB, A
    PRITCHETT, DB
    BACH, A
    SHIVERS, BD
    SEEBURG, PH
    EMBO JOURNAL, 1989, 8 (13): : 4025 - 4034
  • [39] Loss of dopamine-D2 receptor binding sites in parkinsonian plus syndromes
    Hierholzer, J
    Cordes, M
    Venz, S
    Schelosky, L
    Harisch, C
    Richter, W
    Keske, U
    Hosten, N
    Mäurer, J
    Poewe, W
    Felix, R
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (06) : 954 - 960
  • [40] AN ANTIPEPTIDE ANTIBODY THAT RECOGNIZES THE DOPAMINE-D2 RECEPTOR FROM BOVINE STRIATUM
    PLUG, MJ
    DIJK, J
    MAASSEN, JA
    MOLLER, W
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1992, 206 (01): : 123 - 130